Work

Wearing-off symptoms persist in the majority of patients with multiple sclerosis after switching from natalizumab to ocrelizumab

Year: 2025

Type: article

Abstract: BACKGROUND: Wearing-off symptoms (WoS) are common in multiple sclerosis (MS) patients treated with biologicals. OBJECTIVES: To investigate the occurrence of WoS in patients with MS who switch from natalizumab to ocrelizumab treatment. METHODS: We evaluated WoS in patients who completed a WoS questionnaire during both natalizumab and ocrelizumab treatment. RESULTS: Among the included patients (N = 33), those with WoS during natalizumab treatment had higher odds of experiencing WoS during subsequent ocrelizumab treatment, compared to those without WoS during natalizumab treatment. CONCLUSIONS: These findings could be valuable for patient counselling, though validation in a larger cohort is desired.

Source: Journal of the Neurological Sciences

DOI: 10.1016/j.jns.2025.125652